{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:39:02Z","timestamp":1792535942520,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01616-6","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T09:11:00Z","timestamp":1792487460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Later-line Treatment Selection in Metastatic Colorectal Cancer: Trifluridine\/Tipiracil Plus Bevacizumab, Regorafenib, and Fruquintinib"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"1616_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1616_CR2","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.annonc.2026.03.005","volume":"37","author":"C Cremolini","year":"2026","unstructured":"Cremolini C, Chalabi M, Elez E, ESMO Guidelines Committee, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(6):759\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2026.03.005.","journal-title":"Ann Oncol"},{"key":"1616_CR3","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1007\/s10147-025-02899-8","volume":"30","author":"Y Kinugasa","year":"2025","unstructured":"Kinugasa Y, Uehara K, Yamaguchi K, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer. Int J Clin Oncol. 2025;30:2410\u201363. https:\/\/doi.org\/10.1007\/s10147-025-02899-8.","journal-title":"Int J Clin Oncol"},{"key":"1616_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388:1657\u201367. https:\/\/doi.org\/10.1056\/NEJMoa2214963.","journal-title":"N Engl J Med"},{"key":"1616_CR5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X.","journal-title":"Lancet"},{"key":"1616_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402:41\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(23)00772-9.","journal-title":"Lancet"},{"key":"1616_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1414325.","journal-title":"N Engl J Med"},{"key":"1616_CR8","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 2017;18:1172\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(17)30425-4.","journal-title":"Lancet Oncol"},{"key":"1616_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:412\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(19)30827-7.","journal-title":"Lancet Oncol"},{"key":"1616_CR10","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018;319:2486\u201396. https:\/\/doi.org\/10.1001\/jama.2018.7855.","journal-title":"JAMA"},{"key":"1616_CR11","doi-asserted-by":"publisher","first-page":"115644","DOI":"10.1016\/j.ejca.2025.115644","volume":"227","author":"J Taieb","year":"2025","unstructured":"Taieb J, Modest DP, Fakih M, et al. Impact of trifluridine\/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. Eur J Cancer. 2025;227:115644. https:\/\/doi.org\/10.1016\/j.ejca.2025.115644.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1616_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.clcc.2024.12.002","volume":"24","author":"J Taieb","year":"2025","unstructured":"Taieb J, Fakih M, Tabernero J, et al. Impact of treatment with trifluridine\/tipiracil in combination with bevacizumab on health-related quality of life and performance status in refractory metastatic colorectal cancer: an analysis of the phase III SUNLIGHT trial. Clin Colorectal Cancer. 2025;24(2):180\u2013e1874. https:\/\/doi.org\/10.1016\/j.clcc.2024.12.002.","journal-title":"Clin Colorectal Cancer"},{"key":"1616_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(15)70156-7.","journal-title":"Lancet Oncol"},{"key":"1616_CR14","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","volume":"20","author":"TS Bekaii-Saab","year":"2019","unstructured":"Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20:1070\u201382. https:\/\/doi.org\/10.1016\/S1470-2045(19)30272-4.","journal-title":"Lancet Oncol"},{"key":"1616_CR15","doi-asserted-by":"publisher","first-page":"oyae360","DOI":"10.1093\/oncolo\/oyae360","volume":"30","author":"C Eng","year":"2025","unstructured":"Eng C, Dasari A, Lonardi S, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. Oncologist. 2025;30:oyae360. https:\/\/doi.org\/10.1093\/oncolo\/oyae360.","journal-title":"Oncologist"},{"key":"1616_CR16","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s10147-025-02852-9","volume":"30","author":"D Kotani","year":"2025","unstructured":"Kotani D, Yoshino T, Masuishi T, et al. Efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer: a FRESCO-2 subgroup analysis of patients enrolled in Japan. Int J Clin Oncol. 2025;30:2043\u201352. https:\/\/doi.org\/10.1007\/s10147-025-02852-9.","journal-title":"Int J Clin Oncol"},{"key":"1616_CR17","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1111\/hepr.70176","volume":"56","author":"T Hori","year":"2026","unstructured":"Hori T, Yamamoto K, Aoi H, et al. Preventive effect of mineralocorticoid receptor antagonists against proteinuria induced by atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study. Hepatol Res. 2026;56:1225\u201334. https:\/\/doi.org\/10.1111\/hepr.70176.","journal-title":"Hepatol Res"},{"key":"1616_CR18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2217\/fon-2020-0875","volume":"17","author":"R Xu","year":"2021","unstructured":"Xu R, Qin S, Guo W, et al. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase III trial. Future Oncol. 2021;17:1339\u201350. https:\/\/doi.org\/10.2217\/fon-2020-0875.","journal-title":"Future Oncol"},{"key":"1616_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41591-023-02240-8","volume":"29","author":"J van de Haar","year":"2023","unstructured":"van de Haar J, Ma X, Ooft SN, et al. Codon-specific KRAS mutations predict survival benefit of trifluridine\/tipiracil in metastatic colorectal cancer. Nat Med. 2023;29:605\u201314. https:\/\/doi.org\/10.1038\/s41591-023-02240-8.","journal-title":"Nat Med"},{"key":"1616_CR20","doi-asserted-by":"publisher","first-page":"102945","DOI":"10.1016\/j.esmoop.2024.102945","volume":"9","author":"J Tabernero","year":"2024","unstructured":"Tabernero J, Taieb J, Fakih M, et al. Impact of KRAS G12 mutations on survival with trifluridine\/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial. ESMO Open. 2024;9:102945. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102945.","journal-title":"ESMO Open"},{"issue":"5","key":"1616_CR21","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/jnci\/djaf385","volume":"118","author":"G Maddalena","year":"2026","unstructured":"Maddalena G, van der Pol Y, Villarreal OE, et al. Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with\/without bevacizumab. J Natl Cancer Inst. 2026;118(5):903\u20138. https:\/\/doi.org\/10.1093\/jnci\/djaf385.","journal-title":"J Natl Cancer Inst"},{"key":"1616_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S1470-2045(15)00138-2","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015;16:937\u201348. https:\/\/doi.org\/10.1016\/S1470-2045(15)00138-2.","journal-title":"Lancet Oncol"},{"key":"1616_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.21037\/cco-2026-1-0018","volume":"15","author":"B Sapapsap","year":"2026","unstructured":"Sapapsap B, Champarhorm S, Pongpun A, et al. Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Chin Clin Oncol. 2026;15:42. https:\/\/doi.org\/10.21037\/cco-2026-1-0018.","journal-title":"Chin Clin Oncol"},{"key":"1616_CR24","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1093\/oncolo\/oyad296","volume":"29","author":"Y Kito","year":"2024","unstructured":"Kito Y, Kawakami H, Mitani S, et al. Trifluridine\/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). Oncologist. 2024;29:e330\u20136. https:\/\/doi.org\/10.1093\/oncolo\/oyad296.","journal-title":"Oncologist"},{"issue":"10517","key":"1616_CR25","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/S0140-6736(25)02025-2","volume":"406","author":"JR Hecht","year":"2025","unstructured":"Hecht JR, Park YS, Tabernero J, et al. STELLAR-303 study investigators. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. Lancet. 2025;406(10517):2360\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(25)02025-2.","journal-title":"Lancet"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01616-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:01:59Z","timestamp":1792533719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1616"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01616-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This article is a narrative review and did not involve human participants, human data, or animal experiments.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tamotsu Sagawa has received lecture fees from Ono Pharmaceutical, Bristol Myers Squibb, AstellasPharma, Eli Lilly Japan, MSD, and Takeda Pharmaceutical. The other authors declare no relevantfinancial or non-financial interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"242"}}